# Plenary Session 2: Landscape Measles Aerosol Vaccine Measles Vaccine, Dry Powder (Inhalable)

**Next-Generation Vaccine Delivery Technology Meeting**Geneva, Switzerland

Name: Dr.S.S.Jadhav

Email: ssj@seruminstitute.com


Title: Executive Director SSI

Date: February 18, 2014

## Technology Description:


Respiratory delivery
 of the currently
 available freeze dried
 measles vaccine







Phase 1 measles aerosol vaccine:

No. of adverse events in 145 healthy measles immune volunteers 1-35 years of age, India - 2007-08



### Measles Aerosol Vaccine Phase II / III RCT





#### **Status:**


- ✓ Bench testing
- ✓ Animal immunogenicity
- ✓ Animal Toxicity



- ✓ Phase 1 in healthy adults
- ✓ Phase II/III in adults
- Usability and acceptability
- ✓ Cost and ICEA

#### **Benefits:**

- Non injectable, easier to administer
- No waste disposal
- Similar cost per dose



#### **Challenges:**

- Need demonstration studies with MR to further document benefits
- Resources to conduct demonstration studies

#### 40 children vaccinated



Injectable route



Aerosol route

#### Measles Aerosol Vaccine: Opportunities ¬Way Forward

### Global Public Health Challenge:

#### **Technology Availability:**

Could be available in 3-5
years time if funding for
trial and demonstration
studies with MR
recommended by SAGE
were conducted

